Ann Dermatol.  2015 Aug;27(4):460-462. 10.5021/ad.2015.27.4.460.

A Case of Gonadotropin-Releasing Hormone Agonist-Induced Sterile Abscess Showing a Good Response to Systemic Steroid Therapy

• So BJ
• Lee JM
• Jung SK
• Kim IH
• Son SW

• KMID: 2171511
• DOI: http://doi.org/10.5021/ad.2015.27.4.460

Abstract

No abstract available.

MeSH Terms

Abscess*
Gonadotropin-Releasing Hormone*
Gonadotropin-Releasing Hormone

Figure

• 

  Fig. 1 Painful tender erythematous subcutaneous swelling on abdomen. (A) Before treatment. (B) After 4 weeks of systemic steroid therapy.

• 

  Fig. 2 Histologic slide stained with hematoxylin and eosin reveals neutrophilic and eosinophilic infiltrates in the reticular dermis.

Reference

1. Limonta P, Manea M. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treat Rev. 2013; 39:647–663.

2. Choi S, Lee AK. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf. 2011; 3:107–119.

3. Gnanaraj J, Saif MW. Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol. 2010; 29:224–227.

4. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr. 1992; 121:634–640.

5. Kim JM, Shin YL. Sterile abscess formation associated with two different forms of gonadotropin-releasing hormone agonist in central precocious puberty. Ann Pediatr Endocrinol Metab. 2012; 17:184–188.